semaglutide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42605535
Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.
Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.
- 저자
- Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto
- 저널
- Diabetes, obesity & metabolism
- 공개일
- 2026 Aug 17
- 연구 유형
- 기타
- DOI
- 10.1111/dom.71233
문헌 요약
Type 2 diabetes drives the progression of metabolic dysfunction-associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium-glucose cotransporter 2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves liver histology in adults with biopsy-proven MASH and type 2 diabetes. In this 5…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.